Body: <p><em>Apologies if the question is out of the scope of the bioinformatics SE. Please feel free to close it if it is the case.</em></p>
  <p>Recently, I have been going into a rabbit hole of papers that discuss the progress of sequencing technologies, from the earliest attempts to Sanger, massively parallel sequencing, and long-read sequencing.</p>
  <p>To my surprise, I was not able to find any recent reference that direclty highlights Illumina's market dominance. The closest I could find was the <a href="https://academic.oup.com/nar/article/39/suppl_1/D19/2505848" rel="nofollow noreferrer">2010 SRA paper</a> (&quot;Almost 80% [...]&quot;) that briefly describes the proportion of records per platform or <a href="https://genomebiology.biomedcentral.com/articles/10.1186/gb4168" rel="nofollow noreferrer">this paper</a> that alludes to Illumina's monopoly. How come it seems so difficult to find recent reports on the use of each sequencing platform?</p>
  <p>Am I missing something there, or am I just looking for something that is not that interesting? To be fair, it's probably easier to query the SRA directly to get my answer.</p>
  
Comments.ContentLicense: CC BY-SA 4.0
Comments.CreationDate: 2023-08-03T19:04:00.580Z
Comments.Text: Welcome to the site. Personally (just my opinion) this is much more suited for Biology SE, however someone here may know the answer.
Comments.UserDisplayName: M__
Comments.ContentLicense: CC BY-SA 4.0
Comments.CreationDate: 2023-08-04T09:39:59.597Z
Comments.Text: I’m voting to close this question because it is neither really a bioinformatic question, not suited for biology SE. I recommend a google search for "Illumina sequencing market share" which for me yielded some interesting articles, mainly from business-related websites and newspapers. Generally they say that in the (short-read) sequencing field Illumina has a 70-80% share right now which is roughly what I would have intuitively anticipated.
Comments.UserDisplayName: ATpoint
Comments.ContentLicense: CC BY-SA 4.0
Comments.CreationDate: 2023-08-05T12:52:56.087Z
Comments.Text: Yes, I'm afraid this isn't on topic here as it isn't about bioinformatics as a science but about the market dominance of a specific company. For what it's worth, this isn't the kind of thing you would expect to find a scientific paper on, if you want a source to cite, look at newspapers, or market analyses. There is no biological point to be made with respect to which company dominates a given market.
Comments.UserDisplayName: terdon
Tags: <illumina><sra>
Title: Journal article reference for Illumina's "near monopoly"
ThreadText: # Journal article reference for Illumina's "near monopoly"
  
  (Asked by: username_0 on 2023-08-03)
  
  *Apologies if the question is out of the scope of the bioinformatics SE. Please feel free to close it if it is the case.*
  
  Recently, I have been going into a rabbit hole of papers that discuss the progress of sequencing technologies, from the earliest attempts to Sanger, massively parallel sequencing, and long-read sequencing.
  
  To my surprise, I was not able to find any recent reference that direclty highlights Illumina's market dominance. The closest I could find was the [2010 SRA paper](https://academic.oup.com/nar/article/39/suppl_1/D19/2505848) ("Almost 80% [...]") that briefly describes the proportion of records per platform or [this paper](https://genomebiology.biomedcentral.com/articles/10.1186/gb4168) that alludes to Illumina's monopoly. How come it seems so difficult to find recent reports on the use of each sequencing platform?
  
  Am I missing something there, or am I just looking for something that is not that interesting? To be fair, it's probably easier to query the SRA directly to get my answer.
  
  **Tags:** illumina, sra
  
  > **Comments:**
  > **username_1**: Welcome to the site. Personally (just my opinion) this is much more suited for Biology SE, however someone here may know the answer.  
  > **username_2**: I’m voting to close this question because it is neither really a bioinformatic question, not suited for biology SE. I recommend a google search for "Illumina sequencing market share" which for me yielded some interesting articles, mainly from business-related websites and newspapers. Generally they say that in the (short-read) sequencing field Illumina has a 70-80% share right now which is roughly what I would have intuitively anticipated.  
  > **username_3**: Yes, I'm afraid this isn't on topic here as it isn't about bioinformatics as a science but about the market dominance of a specific company. For what it's worth, this isn't the kind of thing you would expect to find a scientific paper on, if you want a source to cite, look at newspapers, or market analyses. There is no biological point to be made with respect to which company dominates a given market.  
  
  ---
  
  ## 0 answers
  
  